In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

Pulmonary embolism: new therapeutic strategies

Venous Thromboembolism


Low risk patients, identified by low clinical scores such as (s)PESI, should be considered for early discharge to home as their mortality on ambulatory anticoagulant treatment is <1%. Studies on new oral anticoagulants (dabigatran, rivaroxaban and apixaban) - as well as results of the Hokusai-VTE trial (edoxaban) revealed during this Congress offer a new quality of treatment, including lower bleeding risk, crucial in early discharged patients.

The optimal treatment strategy in patients at intermediate risk of early death, identified by more comprehensive laboratory cardiovascular assessment, is less clear.

New data from a large prospective randomized trial suggest that patients with RV dysfunction on imaging (echo or CT) and a positive troponin I or T test could benefit from treatment with thrombolysis to prevent early haemodynamic decompensation without, however, reducing all-cause mortality and at the cost of an increased risk of stroke.

Better stratification of bleeding risk, as well as safer thrombolytic regimens are necessary to implement such a strategy in clinical practice. The potential role of low dose and/or local thrombolysis, which could also be enhanced by application of therapeutic intravascular ultrasound, awaits further research.

References


Session Title: Pulmonary embolism: new therapeutic strategies

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.